APA
Riedl M. A., Aygören-Pürsün E., Baker J., Farkas H., Anderson J., Bernstein J. A., Bouillet L., Busse P., Manning M., Magerl M., Gompels M., Huissoon A. P., Longhurst H., Lumry W., Ritchie B., Shapiro R., Soteres D., Banerji A., Cancian M., Johnston D. T., Craig T. J., Launay D., Li H. H., Liebhaber M., Nickel T., Offenberger J., Rae W., Schrijvers R., Triggiani M., Wedner H. J., Dobo S., Cornpropst M., Clemons D., Fang L., Collis P., Sheridan W. P. & Maurer M. (20190807). Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study. : Allergy.
Chicago
Riedl M A, Aygören-Pürsün E, Baker J, Farkas H, Anderson J, Bernstein J A, Bouillet L, Busse P, Manning M, Magerl M, Gompels M, Huissoon A P, Longhurst H, Lumry W, Ritchie B, Shapiro R, Soteres D, Banerji A, Cancian M, Johnston D T, Craig T J, Launay D, Li H H, Liebhaber M, Nickel T, Offenberger J, Rae W, Schrijvers R, Triggiani M, Wedner H J, Dobo S, Cornpropst M, Clemons D, Fang L, Collis P, Sheridan W P and Maurer M. 20190807. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study. : Allergy.
Harvard
Riedl M. A., Aygören-Pürsün E., Baker J., Farkas H., Anderson J., Bernstein J. A., Bouillet L., Busse P., Manning M., Magerl M., Gompels M., Huissoon A. P., Longhurst H., Lumry W., Ritchie B., Shapiro R., Soteres D., Banerji A., Cancian M., Johnston D. T., Craig T. J., Launay D., Li H. H., Liebhaber M., Nickel T., Offenberger J., Rae W., Schrijvers R., Triggiani M., Wedner H. J., Dobo S., Cornpropst M., Clemons D., Fang L., Collis P., Sheridan W. P. and Maurer M. (20190807). Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study. : Allergy.
MLA
Riedl M A, Aygören-Pürsün E, Baker J, Farkas H, Anderson J, Bernstein J A, Bouillet L, Busse P, Manning M, Magerl M, Gompels M, Huissoon A P, Longhurst H, Lumry W, Ritchie B, Shapiro R, Soteres D, Banerji A, Cancian M, Johnston D T, Craig T J, Launay D, Li H H, Liebhaber M, Nickel T, Offenberger J, Rae W, Schrijvers R, Triggiani M, Wedner H J, Dobo S, Cornpropst M, Clemons D, Fang L, Collis P, Sheridan W P and Maurer M. Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study. : Allergy. 20190807.